This week's View summarizes articles about whether there are differences in daily symptom scores on statin, placebo, and no treatment in participants who had abandoned statins; the safety and immunogenicity of heterologous schedules with different coronavirus disease 2019 (COVID-19) vaccines; and the effectiveness of inhaled budesonide in reducing recovery time and rates of COVID-19-related hospital admission or death in people at high risk of an adverse outcome.

Clinical Topics: COVID-19 Hub, Diabetes and Cardiometabolic Disease, Dyslipidemia, Prevention, Lipid Metabolism, Nonstatins, Novel Agents, Statins

Keywords: EaglesEyeView, Adenoviridae, Anti-Asthmatic Agents, Atorvastatin, Body Mass Index, Bronchodilator Agents, Budesonide, Comorbidity, Coronavirus, COVID-19, COVID-19 Vaccines, ACC COVID-19 Podcast, Enzyme-Linked Immunosorbent Assay, Fatigue, Fibric Acids, Genetic Vectors, Hematologic Tests, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Immunity, Immunoglobulin G, Muscle Cramp, Myalgia, Nocebo Effect, Patient Admission, Primary Prevention, Primary Health Care, Risk, RNA, Messenger, SARS-CoV-2, Secondary Prevention, Smartphone, Vaccination, Viral Vaccines, Dyslipidemias

< Back to Listings